Analyst Speak:
“The Biopharmaceutical Contract Manufacturing Market is growing at prominent growth rate over the forecast period 2019-2025 and expected to reach US$ 11,647.3 Mn by 2025, due to upsurge in prevalence chronic diseases such as cancer around the globe”
Precision Business Insights (PBI) in its report titled “Biopharmaceutical Contract Manufacturing Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period from 2019 to 2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.
The global biopharmaceutical contract manufacturing market projected to reach US$ 11,647.3 Mn by 2025. The market is projected to grow at prominent growth rate over the forecast years due to increase in the demand for biopharmaceuticals due to surge in the prevalence of chronic diseases around the globe. For instance, according to WHO 2018 data, approximately 9.6 Mn death occurred due to cancer and approximately 17.9 Mn deaths occurred due to cardiovascular disorders around the world. Moreover, development of strong product pipeline for the biopharmaceuticals, lack of adequate manufacturing facilities, and technological advancements in CMOs for the cell-line development, process development, and scale up are anticipated to bolster the biopharmaceutical contract manufacturing market over the forecast timeframe. However, complexity in the transferring of biological components, limited options available for the production of large volume biopharmaceuticals, and stringent regulatory guidelines for the product approval are the impede the biopharmaceutical contract manufacturing market over the forecast timeframe
Biopharmaceutical contract manufacturing market segmented on the basis of source, product type, service type, application, therapeutic area, and region.
Avail Sample Report of the Market @ https://www.precisionbusinessinsights.com/request-sample?product_id=15549
Oncology Segment Expected to Dominate the Market
Based on therapeutic area, the biopharmaceutical contract manufacturing market is segmented into oncology, autoimmune diseases, cardiovascular diseases, metabolic diseases, infectious diseases, ophthalmology, neurology, respiratory diseases, and others. Among the all therapeutic applications, oncology segment dominated the global biopharmaceutical contract manufacturing market in 2018, and is growing at prominent growth rate over the forecast period owing to strong product pipeline and launch of newer products into market. Moreover, cardiovascular disease segment also creates lucrative opportunities over the forecast timeframe owing to increase in the prevalence of cardiovascular diseases and surge in the adoption of biological products for chronic diseases by physicians.
North America Accounts for Major Revenue Share for Biopharmaceutical Contract Manufacturing Market
Precision Business Insights (PBI), biopharmaceutical contract manufacturing market report analyses the market in different regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa. Among the all regions, North America dominate the global biopharmaceutical contract manufacturing market and the market is expected to grow at prominent growth rate over the forecast years owing to increase in the prevalence of diabetes, renal disorders, and other chronic diseases in U.S. and Canada, and presence of huge number of market players in the region. For instance, according to CDC 2015, approximately 30 Mn Americans have diabetes and another 84 Mn have prediabetes that may leads to type 2 diabetes within 5 years if they are not treated. In addition, Europe biopharmaceutical contract manufacturing market creates lucrative opportunities over the forecast years owing to attractive outsourcing locations for the manufacturing of biopharmaceuticals.
Strategic Alliances and Launch of Newer Products in Biopharmaceutical Contract Manufacturing Market
In August 2017, Fresenius Medical Care acquired NxStage, a home dialysis device maker to strengthen its product portfolio in biopharmaceutical contract manufacturing segment
Key player’s profiles in the report are Lonza Group, Samsung Biologics Co., Ltd., Rentschler Biotechnologie GmbH, Catalent, Inc., Fujifilm Diosynth Biotechnologies, Patheon N.V., Abzena plc, Ajinomoto Althea, Inc., Vetter Pharma International GmbH, WuXi Biologics, Boehringer Ingelheim GmbH, Pfizer CentreOne (contract manufacturing unit of Pfizer, Inc.,), and Cytovance Biologics, Inc.
For More Information @ https://www.precisionbusinessinsights.com/market-reports/global-biopharmaceutical-contract-manufacturing-market/
Detailed Segmentation
By Source
Mammalian
Non-mammalian
By Product
Biologics
Monoclonal Antibodies (MAbs)
Recombinant Proteins
Vaccines
Antisense, RNAi, & Molecular Therapy
Others
Biosimilars
By Service
Process Development
Downstream
Upstream
Fill & Finish Operations
Analytical & QC Studies
Packaging
By Application
Commercial
Clinical
By Therapeutic Area
Oncology
Cardiovascular Diseases
Metabolic Disorders
Neurology
Respiratory Diseases
Hematology
Autoimmune Diseases
Others
Geography
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Russia
Poland
Rest of Europe
Asia-Pacific
Japan
China
India
Australia & New Zealand
ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
South Korea
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Middle East and Africa (MEA)
Gulf Cooperation Council (GCC) Countries
Israel
South Africa
Rest of MEA
About Us:
Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights.
Contact Us:
Shreya Paul
Senior Business Development Executive
Email @
[email protected]
Call @ +1-866-598-1553
Precision Business Insights